News | April 06, 2022
ENTOD Pharma bullish on Macushield sales
Macushield tablets assist with age-related macular degeneration, diabetic retinopathy and improves overall vision
Macushield tablets assist with age-related macular degeneration, diabetic retinopathy and improves overall vision
Ind-Ra maintains a neutral outlook for healthcare in FY23
The partnership demonstrates increasing adoption of tetra data to create unrestricted innovation
The new facility is scheduled to start operation in the first half of 2024
Highlighted as game changer in drug development & delivery special feature on innovative technologies for improving drug solubility and bioavailability
New high-throughput, no-wash assays contribute to the development, manufacture and quality control of safer, more effective biotherapeutics
During her tenure at the University of South Florida Dr. Hunter was responsible for managing the patent portfolio associated with Alzamend’s two product candidates, AL001 and AL002
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
It is currently available in tablet and injectable dosage forms
It also secures US $ 10 million for US launch and commercialization
Subscribe To Our Newsletter & Stay Updated
